Biblio
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools. Arch Toxicol. 2020.
. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018;24(13):3582-3592.
MicroRNA-mediated maturation of human pluripotent stem cell-derived cardiomyocytes: Towards a better model for cardiotoxicity?. Food Chem Toxicol. 2016.
. Predicting oncology Drug-Induced cardiotoxicity with Donor-Specific iPSC-CMs-a proof-of-Concept study with doxorubicin. Toxicol Sci. 2024.
Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations. Regul Toxicol Pharmacol. 2020:104756.
Sex-related Differences in Drug-induced QT Prolongation and Torsades de Pointes: a New Model System with Human iPSC-CMs. Toxicol Sci. 2018.
. Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment. Toxicol Sci. 2022.
. Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms. Circ Res. 2019;125(9):855-867.